Acutus Medical, Inc., an arrhythmia management company, designs, manufactures, and markets a range of tools for catheter-based ablation procedures to treat various arrhythmias in the United States and internationally. Its product portfolio includes novel access sheaths, transseptal crossing tools, diagnostic and mapping catheters, conventional and contact force ablation catheters, and mapping and imaging consoles and accessories, as well as supporting algorithms and software programs. Acutus Medical, Inc. was incorporated in 2011 and is based in Carlsbad, California.
IPO Year: 2020
Exchange: NASDAQ
Website: acutusmedical.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/20/2022 | Buy → Neutral | BTIG | |
| 1/14/2022 | $10.00 → $3.00 | Buy → Hold | Canaccord Genuity |
| 11/15/2021 | Neutral → Underweight | JP Morgan | |
| 11/12/2021 | Neutral → Underweight | JP Morgan | |
| 11/12/2021 | $18.00 → $10.00 | Buy | Canaccord Genuity |
| 10/22/2021 | $10.00 | Neutral | Goldman |
| 7/15/2021 | $11.00 → $18.00 | Hold → Buy | Canaccord Genuity |
10-K - Acutus Medical, Inc. (0001522860) (Filer)
8-K - Acutus Medical, Inc. (0001522860) (Filer)
SCHEDULE 13D/A - Acutus Medical, Inc. (0001522860) (Subject)
15-15D - Acutus Medical, Inc. (0001522860) (Filer)
EFFECT - Acutus Medical, Inc. (0001522860) (Filer)
EFFECT - Acutus Medical, Inc. (0001522860) (Filer)
SCHEDULE 13D/A - Acutus Medical, Inc. (0001522860) (Subject)
S-8 POS - Acutus Medical, Inc. (0001522860) (Filer)
S-8 POS - Acutus Medical, Inc. (0001522860) (Filer)
S-8 POS - Acutus Medical, Inc. (0001522860) (Filer)
4 - Acutus Medical, Inc. (0001522860) (Issuer)
4 - Acutus Medical, Inc. (0001522860) (Issuer)
4 - Acutus Medical, Inc. (0001522860) (Issuer)
4 - Acutus Medical, Inc. (0001522860) (Issuer)
4 - Acutus Medical, Inc. (0001522860) (Issuer)
4 - Acutus Medical, Inc. (0001522860) (Issuer)
4 - Acutus Medical, Inc. (0001522860) (Issuer)
4 - Acutus Medical, Inc. (0001522860) (Issuer)
4 - Acutus Medical, Inc. (0001522860) (Issuer)
4 - Acutus Medical, Inc. (0001522860) (Issuer)
CARLSBAD, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. ("Acutus" or the "Company") (OTC:AFIB) today reported results for the full year of 2024. Recent Highlights: 2024 Revenue from Continuing Operations of $20.2 million grew 181% year-over-year, from $7.2 million last year.Operating loss for continuing operations was $0.1 million, compared to 11.7 million last year.Recorded $10.8 million in gain on sale of business, an increase of 19% compared to last year.Cash, cash equivalents, marketable securities and restricted cash were $14.0 million as of December 31, 2024. Full Year 2024 Financial ResultsRevenue from Continuing Operations was $20.2 million for 2024, an increas
CARLSBAD, Calif., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. ("Acutus" or the "Company") (NASDAQ:AFIB), today announced a realignment of resources and operational downsizing. Dr. Shaden Marzouk, Chairperson of the Board of Directors of Acutus, commented, "Following an extensive strategic review by the Company's Board of Directors, we are taking the hard but necessary steps to reduce the size of our organization while complying with our remaining obligations to Medtronic for the production of left-heart access products." Takeo Mukai, CEO & CFO of Acutus, added, "The operational downsizing impacts our team, and it is difficult to part with our valued and highly talented colleag
CARLSBAD, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. ("Acutus" or the "Company") (OTC:AFIB) today reported results for the third quarter and year-to-date of 2024. Recent Highlights: Third quarter revenue from Continuing Operations of $5.3 million grew 156% year-over-year, from $2.1 million in the same quarter last year.Operating income for continuing operations was $0.1 million, an improvement of 119% compared to the same period last year.Recorded $2.4 million in gain on sale of business, a decrease of 8% compared to the same period last year.Cash, cash equivalents, marketable securities and restricted cash were $12.6 million as of September 30, 2024. Thi
CARLSBAD, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. ("Acutus" or the "Company") (OTC:AFIB) today reported results for the second quarter and year-to-date of 2024. Recent Highlights: Second quarter revenue from Continuing Operations of $4.1 million grew 172% year-over-year, from $1.5 million in the same quarter last year.Operating expenses for continuing operations were $2.2 million, a reduction of 47% compared to the same period last year.Recorded $2.9 million in gain on sale of business, an increase of 38% compared to the same period last year.Cash, cash equivalents, marketable securities and restricted cash were $13.3 million as of June 30, 2024. Second Quarter 20
CARLSBAD, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. ("Acutus" or the "Company") (OTC:AFIB) today reported results for the first quarter of 2024. Recent Highlights: First quarter revenue from Continuing Operations of $3.6 million grew 192% year-over-year, from $1.2 million in the same quarter last year..Operating expenses for continuing operations were $3.3 million, a reduction of 38% compared to the same period last year.Recorded $2.8 million in gain on sale of business, an increase of 131% compared to the same period last year.Cash, cash equivalents, marketable securities and restricted cash were $20.0 million as of March 31, 2024. First Quarter 2024 Financial
CARLSBAD, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. ("Acutus" or the "Company") (NASDAQ:AFIB) today reported results for the fourth quarter and full year ended December 31,2023. Recent Highlights: Announced strategic realignment of resources and corporate restructuring on November 8, 2023 with the objective of optimizing financial position and maximizing free cash flow.The Continuing Operations focuses on the implementation of the business model to shift to solely support the manufacturing and distribution of Medtronic's left-heart access product portfolio.Discontinued Operations relates to the Company's mapping and ablation business that was wound down as part of t
CARLSBAD, Calif., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. ("Acutus" or the "Company") (NASDAQ:AFIB), today announced that, following the Company's announcement of its strategic realignment of resources and corporate restructuring and release of its third quarter results on November 8, 2023, the Company will no longer hold its third quarter results conference call and webcast which was previously scheduled for Monday, November 13, 2023. About Acutus Medical, Inc.Acutus is focused on the production of left-heart access products under its distribution agreement with Medtronic, Inc. Founded in 2011, Acutus is based in Carlsbad, California. Investor Contact:Chad HollisterAcutus
CARLSBAD, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. ("Acutus" or the "Company") (NASDAQ:AFIB) today reported results for the third quarter of 2023. Recent Highlights: Third quarter revenue of $5.2 million grew 44% year-over-year, led by strong growth in distribution revenue from sales of left-heart access products to MedtronicRegistered significant year-over-year reductions in both GAAP and non-GAAP operating expenses and cash burn, resulting from disciplined focus on expense managementAnnounced strategic realignment of resources and corporate restructuring with the objective of optimizing financial position and maximizing free cash flow Third Quarter 2023 Financial
CARLSBAD, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. ("Acutus" or the "Company") (NASDAQ:AFIB), today announced a realignment of resources and corporate restructuring. Scott Huennekens, Chairman of Acutus, commented, "Following an extensive strategic review by the Company's Board of Directors, we are taking the hard but necessary steps to streamline our operations. In light of the current financing environment and the capital investments required to achieve leadership in the electrophysiology (EP) market, we have concluded that the optimal use of the Company's resources is to reallocate capital from our mapping and ablation business to the manufacturing of left-heart a
CARLSBAD, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. ("Acutus") (NASDAQ:AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, announced today that it will release its third quarter 2023 financial results on Monday, November 13, 2023. In conjunction with the release, Acutus will host a conference call and webcast that day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights. To access the live call via telephone, please register in advance using the link here. Upon registering, each participant will receive an email confirmation with dial-in numbers and a
CARLSBAD, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. ("Acutus" or the "Company") (NASDAQ:AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced preliminary unaudited results for the fourth quarter and full year 2022. The Company also announced the appointment of Takeo Mukai as Senior Vice President & Chief Financial Officer. Preliminary Unaudited Fourth Quarter and Full Year 2022 ResultsThe Company expects fourth quarter 2022 revenue of approximately $4.7-$4.9 million compared to $4.4 million in the fourth quarter of 2021. Year-over-year growth was driven by an increase in commercial AcQMap pr
SAN JOSE, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- BrightInsight, Inc., provider of the leading global platform for biopharma and medtech regulated digital health solutions, announced today the appointment of Tamara Elias, M.D., Senior Vice President at Nuance, and Scott Huennekens, executive chairperson at Hyperfine, Wondr Medical, Acutus Medical and Envista Holdings Corporation, to the BrightInsight Advisory Council. Dr. Elias and Huennekens bring deep and complimentary experience to this group of industry experts, who work with BrightInsight leadership to advance the company's vision to transform patient outcomes globally through the power of digital technology. Dr. Elias and Huennek
CARLSBAD, Calif., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Acutus Medical ("Acutus") (NASDAQ:AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced the appointment of Niamh Pellegrini to the Company's Board of Directors, effective August 10, 2021. Ms. Pellegrini has over 20 years of experience in the healthcare industry and, since July 2019, has served as the Chief Commercial Officer of Nevro, Inc., a medical device company dedicated to helping patients suffering from chronic pain achieve lasting relief. "Niamh is an experienced and proven executive and commercial leader," said Vince Burgess, President and CEO of Acutu
CARLSBAD, Calif., March 18, 2021 (GLOBE NEWSWIRE) -- Acutus Medical (Nasdaq: AFIB) today announced the appointment of John Sheridan to the Company's Board of Directors effective March 17, 2021. Since March 2019, Mr. Sheridan has been the President and Chief Executive Officer of Tandem Diabetes Care, Inc., a medical device company specializing in the design, development and commercialization of products for people with insulin-dependent diabetes. He has been a member of Tandem’s Board of Directors since June 2019 and a member of the executive management team since 2013. "John has an accomplished track record of growing medical device companies while consistently creating value for all sta
CARLSBAD, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- Acutus Medical (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced the appointment of Duane Wilder as the company’s Chief Commercial Officer. Mr. Wilder joins Acutus with over 25 years of commercial experience in the medical technology industry. Most recently, Mr. Wilder served as Vice President of US Sales, for the Image Guided Therapy division of Philips, where he had National responsibility for all of Philips’ Image Guided Therapy equipment and service sales, as well as the disposable catheters used with the equipment. Previously, Mr. Wilder held
BTIG downgraded Acutus Medical from Buy to Neutral
Canaccord Genuity downgraded Acutus Medical from Buy to Hold and set a new price target of $3.00 from $10.00 previously
JP Morgan downgraded Acutus Medical from Neutral to Underweight
JP Morgan downgraded Acutus Medical from Neutral to Underweight
Canaccord Genuity reiterated coverage of Acutus Medical with a rating of Buy and set a new price target of $10.00 from $18.00 previously
Goldman initiated coverage of Acutus Medical with a rating of Neutral and set a new price target of $10.00
Canaccord Genuity upgraded Acutus Medical from Hold to Buy and set a new price target of $18.00 from $11.00 previously
Canaccord Genuity reiterated coverage of Acutus Medical with a rating of Hold and set a new price target of $16.00 from $30.00 previously
William Blair downgraded Acutus Medical from Outperform to Market Perform
William Blair downgraded Acutus Medical from Outperform to Mkt Perform and set a new price target of $19.00 from $39.00 previously
CARLSBAD, Calif., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. ("Acutus" or the "Company") (NASDAQ:AFIB), today announced that, following the Company's announcement of its strategic realignment of resources and corporate restructuring and release of its third quarter results on November 8, 2023, the Company will no longer hold its third quarter results conference call and webcast which was previously scheduled for Monday, November 13, 2023. About Acutus Medical, Inc.Acutus is focused on the production of left-heart access products under its distribution agreement with Medtronic, Inc. Founded in 2011, Acutus is based in Carlsbad, California. Investor Contact:Chad HollisterAcutus
CARLSBAD, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. ("Acutus") (NASDAQ:AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, announced today that it will release its third quarter 2023 financial results on Monday, November 13, 2023. In conjunction with the release, Acutus will host a conference call and webcast that day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights. To access the live call via telephone, please register in advance using the link here. Upon registering, each participant will receive an email confirmation with dial-in numbers and a
CARLSBAD, Calif., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. ("Acutus" or the "Company") (NASDAQ:AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today reported results for the second quarter of 2023. Recent Highlights: Second quarter revenue of $5.3 million grew 30% year-over-year, reflecting strong procedure volume growth and improved capital salesQuarterly AcQMap procedure volumes set a new record and increased 21% compared to the second quarter of 2022Received FDA 510K clearance for AcQMap 9 next generation software platform featuring advanced algorithms and automation to improve diagnostic capabil
CARLSBAD, Calif., July 24, 2023 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. ("Acutus") (NASDAQ:AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, announced today that it will release its second quarter 2023 financial results on Monday, August 7, 2023. In conjunction with the release, Acutus will host a conference call and webcast that day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights. To access the live call via telephone, please register in advance using the link here. Upon registering, each participant will receive an email confirmation with dial-in numbers and a uni
CARLSBAD, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. ("Acutus" or the "Company") (NASDAQ:AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today reported results for the first quarter of 2023. Recent Highlights: Reported revenue of $4.2 million for the first quarter of 2023, a 13% increase compared to $3.7 million for the same quarter last year.Continued improvement in financial performance with year-over-year reductions of 58% in GAAP operating expenses, and year-over-year reductions of 39% in both non-GAAP operating expenses and cash burn for the first quarter of 2023.Increased full year revenue outloo
CARLSBAD, Calif., April 28, 2023 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. ("Acutus") (NASDAQ:AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, announced today that it will release its first quarter 2023 financial results on Thursday, May 11, 2023. In conjunction with the release, Acutus will host a conference call and webcast that day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights. To access the live call via telephone, please register in advance using the link here. Upon registering, each participant will receive an email confirmation with dial-in numbers and a uni
CARLSBAD, Calif., April 20, 2023 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. ("Acutus") (NASDAQ:AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced results from the RECOVER AF study. The study, published online in EP Europace, found that patients who received AcQMap-guided ablations for retreatment achieved better outcomes compared to those who underwent traditional anatomical retreatment strategies.1-3 Moreover, the study showed patients who had only undergone pulmonary vein isolation (PVI) before enrollment achieved 91% freedom from atrial fibrillation (AF) at one year, while the entire study population, with v
CARLSBAD, Calif., March 16, 2023 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. ("Acutus" or the "Company") (NASDAQ:AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today reported results for the fourth quarter and full year ended December 31, 2022. Financial statements and other information presented for 2022 is unaudited. Recent Highlights: Reported revenue of $5.0 million for the fourth quarter of 2022, a 14% increase compared to $4.4 million for the same quarter last yearReported revenue of $16.4 million for the full year of 2022, a 5% decrease compared to $17.3 million for the full year of 2021Global mapping procedure volu
CARLSBAD, Calif., March 09, 2023 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. ("Acutus") (NASDAQ:AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, announced today that it will release its fourth quarter and full year 2022 financial results on Thursday, March 16, 2023. In conjunction with the release, Acutus will host a conference call and webcast that day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights. To access the live call via telephone, please register in advance using the link here. Upon registering, each participant will receive an email confirmation with dial-i
CARLSBAD, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. ("Acutus" or the "Company") (NASDAQ:AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today reported results for the third quarter of 2022. Recent Updates: Reported revenue of $3.6 million in the third quarter of 2022, compared to $4.6 million in the same quarter last yearGlobal mapping procedures volumes increased 17% from the same quarter last yearGenerated significant year-over-year reductions in operating expenses and cash burn for the third quarter of 2022Submitted US premarket approval (PMA) application for the AcQBlate Force-Sensing Ablation Ca
SC 13D/A - Acutus Medical, Inc. (0001522860) (Subject)
SC 13G/A - Acutus Medical, Inc. (0001522860) (Subject)
SC 13G - Acutus Medical, Inc. (0001522860) (Subject)
SC 13D/A - Acutus Medical, Inc. (0001522860) (Subject)
SC 13G/A - Acutus Medical, Inc. (0001522860) (Subject)
SC 13D/A - Acutus Medical, Inc. (0001522860) (Subject)
SC 13D/A - Acutus Medical, Inc. (0001522860) (Subject)
SC 13G - Acutus Medical, Inc. (0001522860) (Subject)
SC 13D/A - Acutus Medical, Inc. (0001522860) (Subject)
SC 13D/A - Acutus Medical, Inc. (0001522860) (Subject)